Novocure NVCR 深 沪
等待开盘 11-04 09:30:00 美东时间
12.27
-0.540
-4.22%
华盛通- 最 高12.80
- 今 开12.80
- 成交量 80.90万股
- 最 低 12.19
- 昨 收 12.81
- 总市值 13.74亿
- 52周最高 34.13
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 10.87
- 委 比 36.76%
- 总股本 1.12亿
- 历史最高 232.76
- 量 比 0.72
- 振 幅 4.76%
- 历史最低 5.95
- 每 手 1
- 风险率 5.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
JP Morgan Maintains Neutral on NovoCure, Lowers Price Target to $23
JP Morgan analyst Jessica Fye maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target from $25 to $23.
10-27 22:36
Novocure To Present Final Results From Phase 3 METIS Trial Of Tumor Treating Fields Therapy For Brain Metastases From NSCLC At 2025 ASTRO
METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following stereotactic radiation of the metastasesResults from the METIS trial published in the International Journal of Radiation Oncology Biology and Physics
09-30 04:32
Japan's Ministry Of Health, Labour And Welfare Approves Novocure's Optune Lua For Concurrent Use With PD-1/PD-L1 Inhibitors For Adult Patients With Unresectable Advanced/Recurrent Non-small Cell Lung Cancer Who Have Progressed On Or After Platinum-Based Chemotherapy
Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical
09-15 19:03
ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma
All five patients in a trial with recurrent glioblastoma given a combination of ImmunityBio's (NASDAQ:IBRX) natural killer (NK) cell therapy Anktiva and Novocure's (NASDAQ:NVCR) Optune Gio Tumor Treat...
08-26 23:21
最新！10款医疗器械进入创新通道
2025年8月5日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第7号），有10款产品进入创新通道。 1.产品名称：产前胎儿畸形...
08-06 11:56
Top 3 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to b...
07-28 18:52
美股周涨跌榜 | 本周飙升568%！Abivax S.A.新药III期研究成功；CRO股Medpace周涨超43%
本周飙升568%！生物技术公司Abivax S.A.溃疡性结肠炎口服药物III期研究成功；CRO股Medpace周涨超43%，Q2营收和EBITDA均超预期>>
07-26 10:23
